Due to health issues, this site is no longer maintained and will be shut down shortly. |
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.
$4.19 +0.06 (1.33%)
As of 03/27/2023 14:14:19 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.